Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:57:16.347Z.
Calculation as of: 2026-10-06T15:57:16.347Z.
Quote observation: 2026-10-06T15:54:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1ca0602d484fef860d1886a06048f849113dfee726f77a026e2ec96edb2346c6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$83.04M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$85.01M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MediciNova, Inc. (MNOV) | $82.73M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.53M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $83.48M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.45M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $85.13M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $84.78M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.57M | N/A | 12.93x | 47.97x | 47.97x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
